Hum. Reprod. Advance Access published online on May 5, 2005
Human Reproduction, doi:10.1093/humrep/dei042
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Division of Reproductive Medicine, Department of Obstetrics and Gynaecology, Vrije Universiteit Medical Centre, De Boelelaan 1117, PO Box 7057, 1007 MB Amsterdam, The Netherlands
* To whom correspondence should be addressed. The purpose of this review is to examine whether the time has come to replace clomiphene citrate (CC) as the first line therapy for WHO group II (eu-oestrogenic) infertility, the majority of which is associated with polycystic ovary syndrome. CC has been the first line therapy for these cases for the last 40 years. It is a simple, cheap treatment, almost devoid of side effects which yields a single live birth rate of
Received November 12, 2004
Revised February 13, 2005
Accepted April 3, 2005
Article
Clomiphene citrate--end of an era? a mini-review
Roy Homburg, E-mail: R.Homburg{at}vumc.nl
![]()
Abstract
25% of starters. Non-response to CC and the gap between ovulation and pregnancy rates have variously been attributed to its anti-estrogen effects, and high LH and androgen concentrations. Three possible contenders for the replacement of CC as first-line treatment are scrutinized: metformin, aromatase inhibitors and low-dose FSH. Each has their advantages and disadvantages, but none of them, while showing much potential promise, has been proven, as yet, to be a feasible replacement for CC in this role. For CC, it may not yet be the end of an era but it may be the beginning of the end.![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
K. R Eckmann and D. R Kockler Aromatase Inhibitors for Ovulation and Pregnancy in Polycystic Ovary Syndrome Ann. Pharmacother., July 1, 2009; 43(7): 1338 - 1346. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Shao, M. Nutu, B. Weijdegard, E. Egecioglu, J. Fernandez-Rodriguez, L. Karlsson-Lindahl, K. Gemzell-Danielsson, C. Bergh, and H. Billig Clomiphene Citrate Causes Aberrant Tubal Apoptosis and Estrogen Receptor Activation in Rat Fallopian Tube: Implications for Tubal Ectopic Pregnancy Biol Reprod, June 1, 2009; 80(6): 1262 - 1271. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Sanna, M. C. Mostallino, L. Murru, M. Carta, G. Talani, S. Zucca, M. L. Mura, E. Maciocco, and G. Biggio Changes in Expression and Function of Extrasynaptic GABAA Receptors in the Rat Hippocampus during Pregnancy and after Delivery J. Neurosci., February 11, 2009; 29(6): 1755 - 1765. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. A. Cataldo, H. X. Barnhart, R. S. Legro, E. R. Myers, W. D. Schlaff, B. R. Carr, M. P. Diamond, S. A. Carson, M. P. Steinkampf, C. Coutifaris, et al. Extended-Release Metformin Does Not Reduce the Clomiphene Citrate Dose Required to Induce Ovulation in Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., August 1, 2008; 93(8): 3124 - 3127. [Abstract] [Full Text] [PDF] |
||||
![]() |
The Thessaloniki ESHRE/ASRM-Sponsored PCOS Consens Consensus on infertility treatment related to polycystic ovary syndrome Hum. Reprod., March 1, 2008; 23(3): 462 - 477. [Abstract] [Full Text] [PDF] |
||||
![]() |
B.C.J.M. Fauser, K. Diedrich, P. Devroey, and on behalf of the Evian Annual Reproduction (EVAR) Predictors of ovarian response: progress towards individualized treatment in ovulation induction and ovarian stimulation Hum. Reprod. Update, January 1, 2008; 14(1): 1 - 14. [Abstract] [Full Text] [PDF] |
||||





